BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mortezaee K. CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis. Life Sci 2020;249:117534. [PMID: 32156548 DOI: 10.1016/j.lfs.2020.117534] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 34.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Xie Y, Qin D, Zhong S, Hu X. CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1031706] [Reference Citation Analysis]
2 Habeeb M, Kareem TA, Deepthi KL, Khot VS, Woon YH, Pawar SS. Nanomedicine for targeting the lung cancer cells by interpreting the signaling pathways. Journal of Drug Delivery Science and Technology 2022;77:103865. [DOI: 10.1016/j.jddst.2022.103865] [Reference Citation Analysis]
3 Kuznetsova A, Popova O, Panchenkov D, Dyuzheva T, Ivanov A. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies. Clin Exp Med. [DOI: 10.1007/s10238-022-00886-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Charbel A, Tavernar L, Albrecht T, Brinkmann F, Verheij J, Roos E, Vogel MN, Köhler B, Springfeld C, Brobeil A, Schirmacher P, Singer S, Mehrabi A, Roessler S, Goeppert B. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. Br J Cancer 2022. [PMID: 36068277 DOI: 10.1038/s41416-022-01933-0] [Reference Citation Analysis]
5 Kim NY, Jung YY, Yang MH, Um J, Sethi G, Ahn KS. Isoimperatorin down-regulates epithelial mesenchymal transition through modulating NF-κB signaling and CXCR4 expression in colorectal and hepatocellular carcinoma cells. Cellular Signalling 2022. [DOI: 10.1016/j.cellsig.2022.110433] [Reference Citation Analysis]
6 Sánchez-tirado E, Agüí L, González-cortés A, Yáñez-sedeño P, Pingarrón JM. Biodetection Techniques for Quantification of Chemokines. Chemosensors 2022;10:294. [DOI: 10.3390/chemosensors10080294] [Reference Citation Analysis]
7 Liu Z, Kong Y, Dang Q, Weng S, Zheng Y, Ren Y, Lv J, Li N, Han Y, Han X. Liquid Biopsy in Pre-Metastatic Niche: From Molecular Mechanism to Clinical Application. Front Immunol 2022;13:958360. [DOI: 10.3389/fimmu.2022.958360] [Reference Citation Analysis]
8 Zhu L, Yang F, Wang G, Li Q. CXCR4 disrupts blood-brain barrier and promotes brain metastasis through activation of the PI3K/AKT pathway in lung cancer. World Neurosurg 2022:S1878-8750(22)00942-1. [PMID: 35817351 DOI: 10.1016/j.wneu.2022.07.005] [Reference Citation Analysis]
9 Kwiatkowska I, Hermanowicz JM, Iwinska Z, Kowalczuk K, Iwanowska J, Pawlak D. Zebrafish—An Optimal Model in Experimental Oncology. Molecules 2022;27:4223. [DOI: 10.3390/molecules27134223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zheng S, Liu B, Guan X. The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma. Front Oncol 2022;12:911285. [DOI: 10.3389/fonc.2022.911285] [Reference Citation Analysis]
11 Qiu L, Xu Y, Xu H, Yu B. The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis. BMC Cancer 2022;22:681. [PMID: 35729596 DOI: 10.1186/s12885-022-09756-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vignet P, Coquet J, Auber S, Boudet M, Siegel A, Théret N. Discrete modeling for integration and analysis of large-scale signaling networks. PLoS Comput Biol 2022;18:e1010175. [DOI: 10.1371/journal.pcbi.1010175] [Reference Citation Analysis]
13 El Kheir W, Marcos B, Virgilio N, Paquette B, Faucheux N, Lauzon M. Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment. Pharmaceutics 2022;14:1189. [DOI: 10.3390/pharmaceutics14061189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lv R, Raab M, Wang Y, Tian J, Lin J, Prasad PN. Nanochemistry advancing photon conversion in rare-earth nanostructures for theranostics. Coordination Chemistry Reviews 2022;460:214486. [DOI: 10.1016/j.ccr.2022.214486] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
15 Li H, Wu M, Zhao X. Role of chemokine systems in cancer and inflammatory diseases. MedComm (2020) 2022;3:e147. [PMID: 35702353 DOI: 10.1002/mco2.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wu S, Luo W, Wu X, Shen Z, Wang X. Functional Phenotypes of Peritoneal Macrophages Upon AMD3100 Treatment During Colitis-Associated Tumorigenesis. Front Med 2022;9:840704. [DOI: 10.3389/fmed.2022.840704] [Reference Citation Analysis]
17 Szklener K, Michalski A, Żak K, Piwoński M, Mańdziuk S. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions. Cells 2022;11:1338. [DOI: 10.3390/cells11081338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Mehraj U, Alshehri B, Khan AA, Bhat AA, Bagga P, Wani NA, Mir MA. Expression Pattern and Prognostic Significance of Chemokines in Breast cancer: An Integrated Bioinformatics Analysis. Clinical Breast Cancer 2022. [DOI: 10.1016/j.clbc.2022.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
19 Hu M, Huang L. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance. Adv Drug Deliv Rev 2022;183:114137. [PMID: 35143893 DOI: 10.1016/j.addr.2022.114137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
20 Mehraj U, Mushtaq U, Mir MA, Saleem A, Macha MA, Lone MN, Hamid A, Zargar MA, Ahmad SM, Wani NA. Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications. Semin Cancer Biol 2022:S1044-579X(22)00064-5. [PMID: 35278636 DOI: 10.1016/j.semcancer.2022.03.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
21 Zhang PF, Wang C, Zhang L, Li Q. Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells. Immunotherapy 2022. [PMID: 35232284 DOI: 10.2217/imt-2021-0228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhou M, Zuo Q, Huang Y, Li L. Immunogenic hydrogel toolkit disturbing residual tumor “seeds” and pre-metastatic “soil” for inhibition of postoperative tumor recurrence and metastasis. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
23 Okuyama NCM, Cezar-Dos-Santos F, Trugilo KP, Esposito A, Guembarovski RL, Couto-Filho JD, Watanabe MAE, de Oliveira KB. CXCL12/CXCR4 axis gene variants contribute to an increased vulnerability to HPV infection and cervical oncogenesis. J Cancer Res Clin Oncol 2022. [PMID: 35083551 DOI: 10.1007/s00432-021-03884-0] [Reference Citation Analysis]
24 Cristi F, Gutiérrez T, Hitt MM, Shmulevitz M. Genetic Modifications That Expand Oncolytic Virus Potency. Front Mol Biosci 2022;9:831091. [DOI: 10.3389/fmolb.2022.831091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Honoré B, Andersen MD, Wilken D, Kamper P, d'Amore F, Hamilton-Dutoit S, Ludvigsen M. Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling. Cancers (Basel) 2022;14:247. [PMID: 35008410 DOI: 10.3390/cancers14010247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Morbidelli L. General conclusions and future perspectives. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy 2022. [DOI: 10.1016/b978-0-323-90190-1.00004-4] [Reference Citation Analysis]
27 Ekmekci S, Aktas S. The Concept and Mechanisms of Metastasis. Biomarkers in Carcinoma of Unknown Primary 2022. [DOI: 10.1007/978-3-030-84432-5_2] [Reference Citation Analysis]
28 Maurya SK, Khan P, Rehman AU, Kanchan RK, Perumal N, Mahapatra S, Chand HS, Santamaria-Barria JA, Batra SK, Nasser MW. Rethinking the chemokine cascade in brain metastasis: Preventive and therapeutic implications. Semin Cancer Biol 2021:S1044-579X(21)00302-3. [PMID: 34968667 DOI: 10.1016/j.semcancer.2021.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Luchnik AN. Chromosome instability induced by mutations in TAD anchors leads to tumors. GENOME INSTAB DIS 2021;2:309-329. [DOI: 10.1007/s42764-021-00050-1] [Reference Citation Analysis]
30 Bondoc A, Glaser K, Jin K, Lake C, Cairo S, Geller J, Tiao G, Aronow B. Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma. Commun Biol 2021;4:1049. [PMID: 34497364 DOI: 10.1038/s42003-021-02562-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
31 Hu J, Jiang Q, Shi T, Lin X, Zhao Y, Wang X, Liu X. In Situ Generated and Amplified Oxidative Stress with Metallo‐Nanodrug Assembly for Metastatic Cancer Therapy with High Specificity and Efficacy. Adv Therap 2021;4:2100148. [DOI: 10.1002/adtp.202100148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cao D, Naiyila X, Li J, Huang Y, Chen Z, Chen B, Li J, Guo J, Dong Q, Ai J, Yang L, Liu L, Wei Q. Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment. Front Cell Dev Biol 2021;9:705280. [PMID: 34447750 DOI: 10.3389/fcell.2021.705280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Gao X, Qin S, Wu Y, Chu C, Jiang B, Johnson RH, Kuang D, Zhang J, Wang X, Mehta A, Tew KD, Leone GW, Yu XZ, Wang H. Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. J Clin Invest 2021;131:143119. [PMID: 34255748 DOI: 10.1172/JCI143119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
34 Qiu H, Zhang X, Yu H, Gao R, Shi J, Shen T. Identification of potential targets of triptolide in regulating the tumor microenvironment of stomach adenocarcinoma patients using bioinformatics. Bioengineered 2021;12:4304-19. [PMID: 34348580 DOI: 10.1080/21655979.2021.1945522] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
35 Schuler LA, Murdoch FE. Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. Cancers (Basel) 2021;13:3725. [PMID: 34359625 DOI: 10.3390/cancers13153725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Naїja A, Merhi M, Inchakalody V, Fernandes Q, Mestiri S, Prabhu KS, Uddin S, Dermime S. The role of PAK4 in the immune system and its potential implication in cancer immunotherapy. Cell Immunol 2021;367:104408. [PMID: 34246086 DOI: 10.1016/j.cellimm.2021.104408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
37 Kamihara Y, Murai S, Kikuchi S, Wada A, Murakami J, Dang NH, Sato T. Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report. BMC Gastroenterol 2021;21:270. [PMID: 34187383 DOI: 10.1186/s12876-021-01844-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Lai WY, Mueller A. Latest update on chemokine receptors as therapeutic targets. Biochem Soc Trans 2021;49:1385-95. [PMID: 34060588 DOI: 10.1042/BST20201114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
39 Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci 2021;277:119627. [PMID: 34004256 DOI: 10.1016/j.lfs.2021.119627] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
40 Mortezaee K. Organ tropism in solid tumor metastasis: an updated review. Future Oncology 2021;17:1943-61. [DOI: 10.2217/fon-2020-1103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
41 Li Santi A, Napolitano F, Montuori N, Ragno P. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications. Int J Mol Sci 2021;22:4111. [PMID: 33923400 DOI: 10.3390/ijms22084111] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 23.0] [Reference Citation Analysis]
42 Davenport CF, Scheithauer T, Dunst A, Bahr FS, Dorda M, Wiehlmann L, Tran DDH. Genome-Wide Methylation Mapping Using Nanopore Sequencing Technology Identifies Novel Tumor Suppressor Genes in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3937. [PMID: 33920410 DOI: 10.3390/ijms22083937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
43 Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity 2021;54:859-74. [PMID: 33838745 DOI: 10.1016/j.immuni.2021.01.012] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 71.0] [Reference Citation Analysis]
44 Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 2021;11:5365-86. [PMID: 33859752 DOI: 10.7150/thno.58390] [Cited by in Crossref: 79] [Cited by in F6Publishing: 93] [Article Influence: 79.0] [Reference Citation Analysis]
45 Rusetska N, Kowalski K, Zalewski K, Zięba S, Bidziński M, Goryca K, Kotowicz B, Fuksiewicz M, Kopczynski J, Bakuła-Zalewska E, Kowalik A, Kowalewska M. CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma. J Clin Pathol 2021:jclinpath-2020-206917. [PMID: 33692092 DOI: 10.1136/jclinpath-2020-206917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
46 Daniele S, La Pietra V, Piccarducci R, Pietrobono D, Cavallini C, D'Amore VM, Cerofolini L, Giuntini S, Russomanno P, Puxeddu M, Nalli M, Pedrini M, Fragai M, Luchinat C, Novellino E, Taliani S, La Regina G, Silvestri R, Martini C, Marinelli L. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme. Eur J Pharmacol 2021;897:173936. [PMID: 33581134 DOI: 10.1016/j.ejphar.2021.173936] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
47 Garcia-Sampedro A, Gaggia G, Ney A, Mahamed I, Acedo P. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. J Clin Med 2021;10:566. [PMID: 33546207 DOI: 10.3390/jcm10040566] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
48 Mortezaee K. Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. J Biochem Mol Toxicol 2021;35:e22708. [PMID: 33491255 DOI: 10.1002/jbt.22708] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 26.0] [Reference Citation Analysis]
49 Feng W, Huang W, Chen J, Qiao C, Liu D, Ji X, Xie M, Zhang T, Wang Y, Sun M, Tian D, Fan D, Nie Y, Wu K, Xia L. CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. Theranostics 2021;11:2612-33. [PMID: 33456563 DOI: 10.7150/thno.52199] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
50 陈 岳. Research Progress of PD-1 Inhibitor Combination. PI 2021;10:112-120. [DOI: 10.12677/pi.2021.103015] [Reference Citation Analysis]
51 Hussain S, Peng B, Cherian M, Song JW, Ahirwar DK, Ganju RK. The Roles of Stroma-Derived Chemokine in Different Stages of Cancer Metastases. Front Immunol 2020;11:598532. [PMID: 33414786 DOI: 10.3389/fimmu.2020.598532] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
52 Bassi G, Panseri S, Dozio SM, Sandri M, Campodoni E, Dapporto M, Sprio S, Tampieri A, Montesi M. Scaffold-based 3D cellular models mimicking the heterogeneity of osteosarcoma stem cell niche. Sci Rep 2020;10:22294. [PMID: 33339857 DOI: 10.1038/s41598-020-79448-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
53 Mortezaee K. Redox tolerance and metabolic reprogramming in solid tumors. Cell Biol Int 2021;45:273-86. [PMID: 33236822 DOI: 10.1002/cbin.11506] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
54 Zhang Q, Han Z, Zhu Y, Chen J, Li W. The Role and Specific Mechanism of OCT4 in Cancer Stem Cells: A Review. Int J Stem Cells 2020;13:312-25. [PMID: 32840233 DOI: 10.15283/ijsc20097] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
55 Ryu KJ, Lee JY, Choi ME, Yoon SE, Cho J, Ko YH, Shim JH, Kim WS, Park C, Kim SJ. Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma. Cancers (Basel) 2020;12:E3548. [PMID: 33261029 DOI: 10.3390/cancers12123548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
56 Chin YT, Liu CM, Chen TY, Chung YY, Lin CY, Hsiung CN, Jan YS, Chiu HC, Fu E, Lee SY. 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside-stimulated dental pulp stem cells-derived conditioned medium enhances cell activity and anti-inflammation. J Dent Sci 2021;16:586-98. [PMID: 33854707 DOI: 10.1016/j.jds.2020.10.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Mortezaee K, Najafi M. Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives. Crit Rev Oncol Hematol 2021;157:103180. [PMID: 33264717 DOI: 10.1016/j.critrevonc.2020.103180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 19.5] [Reference Citation Analysis]
58 Ashrafizadeh M, Zarrabi A, Orouei S, Kiavash Hushmandi, Hakimi A, Amirhossein Zabolian, Daneshi S, Samarghandian S, Baradaran B, Najafi M. MicroRNA-mediated autophagy regulation in cancer therapy: The role in chemoresistance/chemosensitivity. Eur J Pharmacol 2021;892:173660. [PMID: 33310181 DOI: 10.1016/j.ejphar.2020.173660] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
59 Khan AQ, Rashid K, Alamodi AA, Raza SS, Uddin S. Recent developments in unraveling signaling mechanisms underlying drug resistance due to cancer stem-like cells. Current Opinion in Pharmacology 2020;54:130-41. [DOI: 10.1016/j.coph.2020.09.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
60 Chatterjee B, Saha P, Bose S, Shukla D, Chatterjee N, Kumar S, Tripathi PP, Srivastava AK. MicroRNAs: As Critical Regulators of Tumor- Associated Macrophages. Int J Mol Sci 2020;21:E7117. [PMID: 32992449 DOI: 10.3390/ijms21197117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
61 Sanfilippo C, Castrogiovanni P, Imbesi R, Nunnari G, Di Rosa M. Postsynaptic damage and microglial activation in AD patients could be linked CXCR4/CXCL12 expression levels. Brain Res 2020;1749:147127. [PMID: 32949560 DOI: 10.1016/j.brainres.2020.147127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
62 Caligiuri A, Pastore M, Lori G, Raggi C, Di Maira G, Marra F, Gentilini A. Role of Chemokines in the Biology of Cholangiocarcinoma. Cancers (Basel) 2020;12:E2215. [PMID: 32784743 DOI: 10.3390/cancers12082215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
63 Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Najafi M. The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives. Int Immunopharmacol 2020;87:106807. [PMID: 32683299 DOI: 10.1016/j.intimp.2020.106807] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
64 Cheng YQ, Wang SB, Liu JH, Jin L, Liu Y, Li CY, Su YR, Liu YR, Sang X, Wan Q, Liu C, Yang L, Wang ZC. Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours. Cell Prolif 2020;53:e12865. [PMID: 32588948 DOI: 10.1111/cpr.12865] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
65 Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T, Sethi G. Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. Int J Mol Sci 2020;21:E4002. [PMID: 32503307 DOI: 10.3390/ijms21114002] [Cited by in Crossref: 94] [Cited by in F6Publishing: 105] [Article Influence: 47.0] [Reference Citation Analysis]
66 Brown JM. Radiation Damage to Tumor Vasculature Initiates a Program That Promotes Tumor Recurrences. Int J Radiat Oncol Biol Phys 2020;108:734-44. [PMID: 32473180 DOI: 10.1016/j.ijrobp.2020.05.028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
67 Wygrecka M, Schaefer L. Between life and death: Epithelial cells in lung pathologies. Cell Signal 2020;72:109652. [PMID: 32325184 DOI: 10.1016/j.cellsig.2020.109652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Scala S, D'Alterio C, Milanesi S, Castagna A, Carriero R, Farina FM, Locati M, Borroni EM. New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM. Vaccines (Basel) 2020;8:E164. [PMID: 32260318 DOI: 10.3390/vaccines8020164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]